Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.